Ocugen, Inc. (OCGN)
| Market Cap | 1.65B |
| Revenue (ttm) | -380 |
| Net Income (ttm) | -47.29M |
| Shares Out | 195.57M |
| EPS (ttm) | -0.27 |
| PE Ratio | n/a |
| Forward PE | 16.03 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21,468,929 |
| Open | 8.03 |
| Previous Close | 8.46 |
| Day's Range | 7.75 - 8.39 |
| 52-Week Range | 0.25 - 18.77 |
| Beta | 4.30 |
| Analysts | Buy |
| Price Target | 8.88 (+6.7%) |
| Est. Earnings Date | Nov 5, 2021 |
About OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development st...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for Ocugen stock is "Buy." The 12-month stock price forecast is 8.88, which is an increase of 6.73% from the latest price.
News
3 Under-the-Radar COVID Stocks
Some COVID-19 stocks are pretty famous. But other lesser-known names are flying high, too.
3 Biotech Stocks That Are Ridiculously Overpriced
They've risen too far, too quickly.
Ocugen Surged on Its Covid Vaccine Emergency Approval in India
OCGN stock has suffered as a Covid-19 vaccine latecomer, but news that Covaxin won emergency approval in India sent shares soaring. The post Ocugen Surged on Its Covid Vaccine Emergency Approval in Indi...
Is Now a Good Time to Buy Ocugen?
There is a lot of uncertainty surrounding this biotech's prospects.
Ocugen Inc. to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic Development Conference
MALVERN, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases...
This Ocugen Stock Rally Makes Little Sense, But Watch Out Going Short
Highly volatile, with a tendency to make unwarranted moves higher, it's best to not go long (or short) OCGN stock. The post This Ocugen Stock Rally Makes Little Sense, But Watch Out Going Short appeared...
Why Shares of Dynavax Technologies, Ocugen, and Valneva Are on the Move Today
These COVID-19 vaccine developers are all moving in response to strong late-stage results for Valneva's VLA2001.
Is Ocugen Stock Heading for a Crash?
The stock soared more than 22% this past week.
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Oct. 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases...
Why Shares of Moderna, Novavax, and Ocugen Are Falling Today
These COVID-19 vaccine makers are sinking on nothing more than good old-fashioned uncertainty.
Ocugen Is a Strong Sell, Vaccine Unlikely to Find Commercial Success
Ocugen has historically had a terrible track record. There's little reason to think its current vaccine effort will end any better for OCGN stock.
Why Ocugen Stock Is Skyrocketing This Week
Positive developments for COVID-19 vaccine Covaxin appear to have kicked off a short squeeze.
OCGN Stock: One Big Reason Why Ocugen Is Climbing Today
Covid-19 vaccine play Ocugen is seeing impressive investor interest today, with OCGN stock seeing double-digit gains at the time of writing. The post OCGN Stock: One Big Reason Why Ocugen Is Climbing To...
Ocugen Stock Needs a Catalyst for Growth That Probably Isn't Coming
InvestorPlace's Louis Navellier believes all Ocugen needs is a catalyst. On Oct. 4, OCGN stock got two.
Is This Going To Be The Next Big Factor For Ocugen (OCGN) Stock?
Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) surged almost 18.5% in Tuesday's regular trading session, extending gains to a second straight day. What Happened: Ocugen's shares extended...
Why Ocugen Stock Is Rallying While Moderna, Novavax, Vaxart Can't Catch Up
Ocugen Inc. (NASDAQ:OCGN) shares were trading higher Tuesday after the Indian government approved Bharat Biotech's COVID-19 vaccine Covaxin, for children between the ages of 2 and 18. Ocugen is partnere...
Hot Penny Stocks for Tuesday: Today's 10 Biggest Movers
Penny stocks are on the move Tuesday and we're taking a look at what's hot among traders of the volatile investments today. The post Hot Penny Stocks for Tuesday: Today's 10 Biggest Movers appeared firs...
OCGN Stock: One Big Reason Ocugen Is Powering Higher Today
OCGN stock is making its investors quite happy this morning and prompting many more to pile in. The company is receiving crucial approval.
Why Ocugen Stock Is on Fire Today
A positive regulatory development in India is sending the biotech's shares higher today.
Ocugen Will Have Value If Its Covid Vaccine Can Get Approved
OCGN stock could be at a full value today given its revenue prospects but could still rise if its Covaxin vaccine gains approval outside India. The post Ocugen Will Have Value If Its Covid Vaccine Can G...
Don't Buy Too Much Into the WHO Hype Surrounding Ocugen Stock
Admittedly, one last boost may still be on the table, if meme traders use subsequent WHO news as reason to send OCGN stock back to double-digit prices. But with its high chances of ultimately collapsing...
Why Did Ocugen Stock Skyrocket On Monday?
Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) surged almost 8.8% in Monday's regular trading session and also gained 11.4% in the after-hours session. What Happened: Ocugen's shares ral...
5 Top Stock Trades for Tuesday: SOFI, LUV, TSLA, T, OCGN
SoFi, Southwest Airlines, Tesla, AT&T and Ocugen were our top stock trades for Tuesday. Now, let's look at how the charts are setting up.
OCUGEN INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate ...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues to investigate O...
WHO To Finalize Nod To Ocugen-Partnered Covaxin Next Week: Sources
The World Health Organization said a decision on the Emergency Use Listing (EUL) of India's COVID-19 vaccine, Covaxin, will be finalized next week. Ocugen Inc (NASDAQ: OCGN) is the U.S. partner for the ...